全文获取类型
收费全文 | 295412篇 |
免费 | 17514篇 |
国内免费 | 397篇 |
专业分类
耳鼻咽喉 | 4220篇 |
儿科学 | 10312篇 |
妇产科学 | 10262篇 |
基础医学 | 44757篇 |
口腔科学 | 7494篇 |
临床医学 | 24081篇 |
内科学 | 55452篇 |
皮肤病学 | 6302篇 |
神经病学 | 21008篇 |
特种医学 | 11689篇 |
外国民族医学 | 48篇 |
外科学 | 46669篇 |
综合类 | 7729篇 |
一般理论 | 160篇 |
预防医学 | 19895篇 |
眼科学 | 6933篇 |
药学 | 20844篇 |
中国医学 | 738篇 |
肿瘤学 | 14730篇 |
出版年
2018年 | 3619篇 |
2017年 | 2672篇 |
2016年 | 3088篇 |
2015年 | 3514篇 |
2014年 | 4607篇 |
2013年 | 7241篇 |
2012年 | 9121篇 |
2011年 | 9518篇 |
2010年 | 6177篇 |
2009年 | 5597篇 |
2008年 | 8716篇 |
2007年 | 9568篇 |
2006年 | 9431篇 |
2005年 | 9012篇 |
2004年 | 8725篇 |
2003年 | 8198篇 |
2002年 | 7781篇 |
2001年 | 13348篇 |
2000年 | 13663篇 |
1999年 | 11381篇 |
1998年 | 2899篇 |
1997年 | 2627篇 |
1996年 | 2483篇 |
1995年 | 2544篇 |
1994年 | 2351篇 |
1992年 | 8329篇 |
1991年 | 8470篇 |
1990年 | 8281篇 |
1989年 | 8092篇 |
1988年 | 7332篇 |
1987年 | 7082篇 |
1986年 | 6728篇 |
1985年 | 6525篇 |
1984年 | 4761篇 |
1983年 | 4114篇 |
1982年 | 2462篇 |
1979年 | 4416篇 |
1978年 | 3219篇 |
1977年 | 2725篇 |
1976年 | 2494篇 |
1975年 | 2828篇 |
1974年 | 3356篇 |
1973年 | 3363篇 |
1972年 | 3117篇 |
1971年 | 2949篇 |
1970年 | 2838篇 |
1969年 | 2585篇 |
1968年 | 2538篇 |
1967年 | 2374篇 |
1966年 | 2264篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
2.
3.
Michels Guido Horn Rudolf Helfen Andreas Hagendorff Andreas Jung Christian Hoffmann Beatrice Jaspers Natalie Kinkel Horst Greim Clemens-Alexander Knebel Fabian Bauersachs Johann Busch Hans-Jörg Kiefl Daniel Spiel Alexander O. Marx Gernot Dietrich Christoph F. 《Der Anaesthesist》2022,71(4):307-310
Die Anaesthesiologie - 相似文献
4.
Two Janus-associated kinase inhibitors (JAKi) (initially ruxolitinib and, more recently, fedratinib) have been approved as treatment options for patients who have intermediate-risk and high-risk myelofibrosis (MF), with pivotal trials demonstrating improvements in spleen volume, disease symptoms, and quality of life. At the same time, however, clinical trial experiences with JAKi agents in MF have demonstrated a high frequency of discontinuations because of adverse events or progressive disease. In addition, overall survival benefits and clinical and molecular predictors of response have not been established in this population, for which the disease burden is high and treatment options are limited. Consistently poor outcomes have been documented after JAKi discontinuation, with survival durations after ruxolitinib ranging from 11 to 16 months across several studies. To address such a high unmet therapeutic need, various non-JAKi agents are being actively explored (in combination with ruxolitinib in first-line or salvage settings and/or as monotherapy in JAKi-pretreated patients) in phase 3 clinical trials, including pelabresib (a bromodomain and extraterminal domain inhibitor), navitoclax (a B-cell lymphoma 2/B-cell lymphoma 2-xL inhibitor), parsaclisib (a phosphoinositide 3-kinase inhibitor), navtemadlin (formerly KRT-232; a murine double-minute chromosome 2 inhibitor), and imetelstat (a telomerase inhibitor). The breadth of data expected from these trials will provide insight into the ability of non-JAKi treatments to modify the natural history of MF. 相似文献
5.
6.
Amarpali Brar Angelika Gruessner Deborah Adey Fasika Tedla Ernie Yap Dheeraj Kaul Nabil Sumrani Devon John Moro O. Salifu 《Transplantation proceedings》2021,53(3):913-919
There is an increase in older-adult renal transplant recipients in United States. The objective of this study was to assess the association between physical function (PF) and patient survival in renal transplant recipients who are aged 65 years or older. Using United Network for Organ Sharing (UNOS) data from 2007 to 2016, renal transplant recipients aged 65 years or older were included. Multivariable Cox regression was used to assess associations between survival and functional status adjusted for age, sex, race, donor quality, diabetes, and dialysis vintage. The study identified 26,721 patients. Patient survival was significantly higher in recipients who needed no assistance and lowest in patients in need of total assistance (P < .0001). In deceased donor (DD) transplants, the relative risk for mortality was 2.06 (1.74-2.43) for total assistance and 1.17 (1.08-1.28) for moderate assistance compared to no assistance (P < .0001). In living donor (LD) transplants, the relative risk of mortality was 1.38 (0.78-2.42) for patients needing total assistance and 1.37 (1.14-1.65) for patients needing moderate assistance compared to patients who did not need assistance (0.003). PF is an independent predictor of post-transplant mortality. Assessment of older potential renal transplant recipients should include assessment and standardization of functional status to counsel about post-transplant survival. 相似文献
7.
8.
9.